Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 known ✓ | O43570 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | LMNA | P02545 | 4/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | LIPE | Q05469 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30869985 | 1.00 | L3MBTL1 (0.38) | L3MBTL1CA12CA7CA14SMN1; SMN2 | |
| Water SCHEMBL28916298 | 0.98 | L3MBTL1 (0.37) | L3MBTL1CA12CA7CA14SMN1; SMN2 | |
| Potassium Ion SCHEMBL8985015 | 0.96 | CA12 (0.38) | L3MBTL1CA12CA7CA14SMN1; SMN2 | |
| SCHEMBL5492629 | 0.96 | CA12 (0.38) | L3MBTL1CA12CA7CA14SMN1; SMN2 | |
| SCHEMBL3293117 | 0.84 | LMNA (0.33) | LMNAGAA | |
| Potassium Ion SCHEMBL5383247 | 0.80 | LMNA (0.33) | LMNAGAA | |
| SCHEMBL15572838 | 0.78 | CA12 (0.41) | L3MBTL1CA12CA7CA14SMN1; SMN2 | |
| SCHEMBL4694756 | 0.78 | CA12 (0.41) | L3MBTL1CA12CA7CA14SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL28285547 | 0.78 | CA12 (0.37) | L3MBTL1CA12CA7CA14SMN1; SMN2 | |
| SCHEMBL49152 | 0.77 | CA12 (0.39) | L3MBTL1CA12CA7CA14SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118531088-A | Blood microorganism detection reagent and preparation method thereof | 南通辉星生物科技有限公司 | 2024-08-23 | — | — | CN | claimed |
| EP-3698799-B1 | HYPERPHOSPHATEMIA TREATMENT AGENT | FUJIFILM CORP (JP) | 2022-01-26 | — | — | EP | claimed |
| US-11147833-B2 | Therapeutic agent for hyperphosphatemia | FUJIFILM CORPORATION (JP) | 2021-10-19 | — | — | US | claimed |
| US-20210121499-A1 | THERAPEUTIC AGENT FOR HYPERPHOSPHATEMIA AND PARTICLES | FUJIFILM CORPORATION (JP) | 2021-04-29 | — | — | US | claimed |
| EP-3698799-A1 | HYPERPHOSPHATEMIA TREATMENT AGENT | FUJIFILM Corporation (JP) | 2020-08-26 | — | — | EP | claimed |
| EP-3698798-A1 | HYPERPHOSPHATEMIA TREATMENT AGENT, AND PARTICLES | FUJIFILM Corporation (JP) | 2020-08-26 | — | — | EP | claimed |
| CN-111246857-A | Therapeutic agent and particle for hyperphosphatemia | 富士胶片株式会社 | 2020-06-05 | — | — | CN | claimed |
| CN-111225674-A | Therapeutic agent for hyperphosphatemia | 富士胶片株式会社 | 2020-06-02 | — | — | CN | claimed |
| US-20190321393-A1 | THERAPEUTIC AGENT FOR HYPERPHOSPHATEMIA AND PARTICLES | FUJIFILM CORPORATION (JP) | 2019-10-24 | — | — | US | claimed |
| US-20190321392-A1 | THERAPEUTIC AGENT FOR HYPERPHOSPHATEMIA | FUJIFILM CORPORATION (JP) | 2019-10-24 | — | — | US | claimed |
| WO-2019078197-A1 | HYPERPHOSPHATEMIA TREATMENT AGENT | 富士フイルム株式会社 | 2019-04-25 | — | — | WO | claimed |
| WO-2019078198-A1 | HYPERPHOSPHATEMIA TREATMENT AGENT, AND PARTICLES | 富士フイルム株式会社 | 2019-04-25 | — | — | WO | claimed |
| CN-118531088-A | Blood microorganism detection reagent and preparation method thereof | 南通辉星生物科技有限公司 | 2024-08-23 | — | — | CN | disclosed |
| CN-114957348-B | Method for synthesizing On-DNA (deoxyribonucleic acid) arylbenzotriazole compound and derivative thereof | 成都先导药物开发股份有限公司 | 2024-02-23 | — | — | CN | disclosed |
| CN-114262372-A | Transcription factor for regulating and controlling osteogenic differentiation of cells and osteogenic differentiated cells | 同济大学 | 2022-04-01 | — | — | CN | disclosed |
| EP-3698799-B1 | HYPERPHOSPHATEMIA TREATMENT AGENT | FUJIFILM CORP (JP) | 2022-01-26 | — | — | EP | disclosed |
| US-5434061-A | Pseudogluconobacter | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1995-07-18 | — | — | US | disclosed |
| EP-0657176-A2 | Composition containing a water-insoluble or slightly water-soluble compound with enhanced water-solubility | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1995-06-14 | — | — | EP | disclosed |
| EP-0634174-A1 | Antianemic composition for veterinary use | Takeda Chemical Industries, Ltd. (JP) | 1995-01-18 | — | — | EP | disclosed |
| EP-0599646-A2 | Production of saccharide carboxylic acids | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1994-06-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190321392-A1 | THERAPEUTIC AGENT FOR HYPERPHOSPHATEMIA | PHPT1, PPIP5K2, PTH1R | CA12 228/4885L3MBTL1 3425/4885CA7 143/4885 |
| US-20210121499-A1 | THERAPEUTIC AGENT FOR HYPERPHOSPHATEMIA AND PARTICLES | PTH1R, SLC34A1, SLC20A1 | CA12 293/4885L3MBTL1 4048/4885CA7 525/4885 |
| US-20190321393-A1 | THERAPEUTIC AGENT FOR HYPERPHOSPHATEMIA AND PARTICLES | PTH1R, SLC34A1, SLC20A1 | CA12 293/4885L3MBTL1 4048/4885CA7 525/4885 |
| US-11147833-B2 | Therapeutic agent for hyperphosphatemia | PHPT1, PPIP5K2, PTH1R | CA12 228/4885L3MBTL1 3425/4885CA7 143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.